Skip to main content
WGSGeneDx Holdings Corp.Sell5.1·$47.29
SellModerate Confidence
Investment thesis

GeneDx is a genomic diagnostics company with 84% revenue growth score and strong analyst consensus, but quality below the investment minimum at 3.9 out of 10, a 30% short interest, and a massive single-quarter earnings miss of -1,408% make this a high-risk situation requiring fundamental stabilization before new entry.

Thesis pillars

  • Quality Just Below Floor↓Deteriorating
  • Severe Earnings Miss Recent→Stable
  • High Short Interest And Put Call↓Deteriorating
  • +1 more pillar — see the Why tab for full reasoning

Pillars as of Jul 3, 2026, based on the 10-K filed Feb 23, 2026· older than 90 days

Full reasoning →

Open full analysis

GeneDx Holdings Corp. (WGS) Stock Analysis

Inst Constrain edge

SellVALUE-TRAP 2/5GrowthQualityModerate Confidence

Healthcare · Diagnostics & Research

Sell if holding. Engine safety override at $47.29: a dimension score below its floor triggers a hard block regardless of the otherwise-positive setup — overall score 5.1/10 and A.R:R 3.4:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 42%; Elevated put/call ratio: 2.53; Below-average business quality.

GeneDx provides exome and whole genome sequencing diagnostic tests focused on pediatric rare and genetic diseases, drawing on a dataset of over 2.5 million tests including more than 1 million exomes and genomes. Revenue derives almost entirely from diagnostic test reports, with... Read more

$47.29+50.9% A.UpsideScore 5.1/10#22 of 32 Diagnostics & Research
QualityF-score5 / 9FCF yield-4.96%
Stop $43.98Analyst target $71.34(−13% haircut)A.R:R 3.4:1
Analyst consensus$82.00+73.4%8 analysts with price targets
$71.34Analyst target
$47.29price
$82.00mean
$102

Sell if holding. Engine safety override at $47.29: a dimension score below its floor triggers a hard block regardless of the otherwise-positive setup — overall score 5.1/10 and A.R:R 3.4:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 42%; Elevated put/call ratio: 2.53; Below-average business quality. Chart setup: No clear chart pattern; technical signals are mixed. Score 5.1/10, moderate confidence.

Passes 7/8 gates (favorable risk/reward ratio, clean insider activity, no SEC red flags, news boost analyst 0.40, earnings proximity 96d clear, semi cycle peak clear, materials cycle peak clear). Fails on weak momentum. Suitability: speculative.

news + 30-day 8-K events · 5-min refresh

Recent developments

updated Nov 14, 2026

Recent Developments — GeneDx Holdings Corp.

Latest item Nov 14, 2026 · Generated 2026-11-18T11:57:28Z.

TrendMatrix Research · upcoming catalyst calendar

Upcoming dated catalysts

Mon, Feb 22, 202796d to earnings· next earnings call

Thesis

Rewards
Recent Analyst detected in news
Risks
Concentration risk — Product: diagnostic test reports
Concentration risk — Supplier: single suppliers for laboratory instruments and materials
Quality below floor (3.2 < 4.0)

Key Metrics

P/E (TTM)—
P/E (Fwd)36.3
Mkt Cap$1.4B
EV/EBITDA-39.9
Profit Mgn-24.1%
ROE-41.4%
Rev Growth5.4%
Beta1.99
DividendNone
Analysts with ratings12

Quality Signals

Piotroski F5/9

Options Flow

P/C2.53bearish
IV107%elevated

Concentration Risks(10-K Item 1A)

  • HIGHProductdiagnostic test reports
    10-K Item 1: 'Substantially all of our revenue for the year ended December 31, 2025 was derived from diagnostic test reports'
  • HIGHSuppliersingle suppliers for laboratory instruments and materials
    10-K Item 1A: 'We rely on a limited number of suppliers or, in some cases, single suppliers, for some of our laboratory instruments and materials'

Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Editorial policy

Show full disclosure ▾

About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.

Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.

Conflicts and positions. People who build TrendMatrix, or entities they control, may hold positions, long or short, in securities it covers, and may trade them at any time. Positions are not disclosed individually. Verdicts are generated by an automated model applied by the same rules to every covered stock, and are not adjusted for any position held by the people who build TrendMatrix. We do not accept payment from issuers for coverage.

No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security.

No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.

Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.

Methodology · Editorial policy & full disclaimer

Rating Breakdown

4 floor-breakers

Volatile — 12.9% daily ATR makes tight stops impractical. Position-size conservatively.static

Short Interest
0.0
Volatility
0.0
Put Call
0.0
Implied Vol
0.0
Days To Cover
2.2
Beta
3.4
Debt Equity
5.7
High short interest justified: 42%Elevated put/call: 2.53High IV: 107%Concentration risks: 2 HIGH (10-K Item 1A — sized via position_sizing, validated via buy_confidence)

Price action weak — below key moving averages, no momentum carry. Needs a base before trend-continuation setups apply.static

Macd
0.0
Obv
1.0
Ma Position
1.0
Rsi
3.5
Volume
7.7
Volume distribution (falling OBV)Below 200-MA, MA slope -10.7%/30d — confirmed downtrend

Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static

Quality Rank
0.7
Growth Rank
2.9
Value Rank
6.6

Unprofitable operations — net margin -24.1%. Quality floor flags this regardless of sector context.static

Roe
0.0
Roa
0.0
Operating Margin
0.0
Net Margin
0.0
Fcf Quality
0.0
Rule Of 40
3.0
Moat
5.1
Piotroski F
5.6
Current Ratio
8.8
Gross Margin
9.8
Cash-burning: FCF -15% of revenueNo competitive moatRule of 40: -10 (fail)
GatesMomentum 2.6<4.5A.R:R 3.4 ≥ 1.5Insider activity: OKNo SEC red flagsNEWS BOOST ANALYST 0.40EARNINGS PROXIMITY 96d clearSEMI CYCLE PEAK CLEARMATERIALS CYCLE PEAK CLEARSuitability: Speculative
RSI
32 · Neutral
↓ 20D MA↓ 50D MA↓ 200D MAGOLDEN CROSSSupport $44.24Resistance $71.53

Price Targets

$44
$71
A.Upside+50.9%
A.R:R3.4:1

Position Sizing

ConvictionNone
Suggested %0%
Max %0%
RegimeSteady

Risk Alerts

! Quality below floor (3.2 < 4.0)
! Value-trap signals (2/5): High leverage (D/E 4.6), Material insider selling (11 sells, 0.05% of cap)
! momentum at 2.6 (below the engine's 4.5 threshold)

Earnings

B
B
B
M
3/4 beats
Next Earnings2027-02-22 (96d)

Verdict History

reverse chrono — latest first
Loading history...
Verdicts are recorded on every nightly pipeline run. Rows capture transitions (verdict flips, score deltas ≥0.3, entry/TP/SL changes). Rows with a ▶ can be expanded to see the change reason. Aggregate cohort performance is tracked in the recommendation ledger.
Frequently Asked Questions
Is WGS stock a buy right now?

Sell if holding. Engine safety override at $47.29: a dimension score below its floor triggers a hard block regardless of the otherwise-positive setup — overall score 5.1/10 and A.R:R 3.4:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 42%; Elevated put/call ratio: 2.53; Below-average business quality. Chart setup: No clear chart pattern; technical signals are mixed. Prior stop was $43.98. Score 5.1/10, moderate confidence.

What is the WGS stock price target?

Analyst target: $71.34 (+50.9% upside). Prior stop was $43.98. Stop-loss: $43.98.

What are the risks of investing in WGS?

Concentration risk — Product: diagnostic test reports; Concentration risk — Supplier: single suppliers for laboratory instruments and materials; Quality below floor (3.2 < 4.0).

Is WGS overvalued or undervalued?

GeneDx Holdings Corp. trades at a P/E of N/A (forward 36.3). TrendMatrix value score: 7.7/10. Verdict: Sell.

What do analysts say about WGS?

12 analysts rate WGS, with a consensus score of 4.3/5. 8 analysts publish price targets averaging $82.

What does GeneDx Holdings Corp. do?GeneDx provides exome and whole genome sequencing diagnostic tests focused on pediatric rare and genetic diseases,...

GeneDx provides exome and whole genome sequencing diagnostic tests focused on pediatric rare and genetic diseases, drawing on a dataset of over 2.5 million tests including more than 1 million exomes and genomes. Revenue derives almost entirely from diagnostic test reports, with approximately 1.5% from outside the United States; the company employs nearly 1,300 people.

Related stocks: CDNA (CareDx, Inc.) · VCYT (Veracyte, Inc.) · CSTL (Castle Biosciences, Inc.) · OPK (Opko Health, Inc.) · BLLN (BillionToOne, Inc.)
Home › Stocks › WGS

Latest news

Latest News

Stock Titan203d ago
Moomoo203d agoEarnings
Investing.com217d agoAnalyst
Stocktwits197d agoEarnings
MSN216d agoAnalyst
MSN206d ago
Yahoo Finance205d agoEarnings
MarketBeat205d agoEarnings
The Globe and Mail198d agoEarnings
Investing.com198d agoEarnings
Yahoo Finance198d agoEarnings
Seeking Alpha198d ago
Quiver Quantitative198d agoEarnings
Moomoo198d agoEarnings
Quiver Quantitative198d ago
Marketscreener.com198d agoEarnings
Marketscreener.com198d agoEarnings
HarianBasis.co198d ago
Insider Monkey198d ago
MarketBeat201d ago
Loading more...